This review highlights the significant advancements in systemic therapies for cervical cancer in 2023, focusing on trials that have transformed the management paradigm for both locally advanced (LACC) and persistent, recurrent, or metastatic (aCC) cervical cancers. Key trials such as INTERLACE, KEYNOTE-A18, BEATcc, innovaTV 301, and DESTINY-PanTumor02 have reported positive results, leading to updated treatment algorithms. INTERLACE demonstrated that induction chemotherapy before concurrent chemoradiotherapy (CCRT) significantly improved progression-free survival (PFS) and overall survival (OS) compared to CCRT alone. KEYNOTE-A18 showed that adding pembrolizumab to CCRT improved PFS and OS in aCC patients. BEATcc confirmed the efficacy of atezolizumab plus chemotherapy in aCC, while innovaTV 301 and DESTINY-PanTumor02 provided evidence for tisotumab vedotin and trastuzumab deruxtecan, respectively, in advanced disease. The review also discusses emerging trends in drug development, including the potential of antibody-drug conjugates (ADCs) and the need for future research to address unmet clinical needs, particularly in rare histological subtypes and patients with prior immune checkpoint inhibitor (ICI) exposure. The authors emphasize the importance of harmonizing trial designs and identifying research opportunities to improve outcomes for women with cervical cancer.This review highlights the significant advancements in systemic therapies for cervical cancer in 2023, focusing on trials that have transformed the management paradigm for both locally advanced (LACC) and persistent, recurrent, or metastatic (aCC) cervical cancers. Key trials such as INTERLACE, KEYNOTE-A18, BEATcc, innovaTV 301, and DESTINY-PanTumor02 have reported positive results, leading to updated treatment algorithms. INTERLACE demonstrated that induction chemotherapy before concurrent chemoradiotherapy (CCRT) significantly improved progression-free survival (PFS) and overall survival (OS) compared to CCRT alone. KEYNOTE-A18 showed that adding pembrolizumab to CCRT improved PFS and OS in aCC patients. BEATcc confirmed the efficacy of atezolizumab plus chemotherapy in aCC, while innovaTV 301 and DESTINY-PanTumor02 provided evidence for tisotumab vedotin and trastuzumab deruxtecan, respectively, in advanced disease. The review also discusses emerging trends in drug development, including the potential of antibody-drug conjugates (ADCs) and the need for future research to address unmet clinical needs, particularly in rare histological subtypes and patients with prior immune checkpoint inhibitor (ICI) exposure. The authors emphasize the importance of harmonizing trial designs and identifying research opportunities to improve outcomes for women with cervical cancer.